buy camtasia studio buy adobe creative suite 6 design standard best price quicken 2009 deluxe cost of windows 8 pro best price adobe acrobat 9.0 standard upgrade cost of adobe flash player 10.2 buy and download windows xp online purchase 2010 microsoft access final cut pro x cheap discount microsoft office 2007 software buy nero 9 download cheap microsoft office 2007 download price of nero 8 cheap windows xp home edition software adobe cs5 web premium price buy word 2003 windows xp cheap office 2013 professional buy adobe framemaker 7.2 cheapest rosetta stone software price of final cut studio buy adobe cs3 master suite download office pro 2010 oem buy outlook 2003 upgrade purchase office 2011 purchase 2007 microsoft outlook buy quicken premier 2010 download buy acrobat 9 extended buy microsoft mappoint 2010 buy adobe photoshop cs2 for pc purchase windows xp software

Oncolytics Biotech Inc. starts patient enrolment in U.S. phase 2 clinical trial investigating Reolysin(R) in combination with paclitaxel and carboplatin

Fri, Sep 12, 2008

Oral Cancer News

Author: press release

Oncolytics Biotech Inc. announced today that that it has started patient enrollment in a Phase 2 clinical trial using intravenous administration of Reolysin(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.

“We are extremely pleased to open the second disease-directed study with Reolysin(R),” said Dr. Mita. “This study represents a promising option for patients with head and neck tumors refractory to standard chemotherapy and we are happy to have the opportunity to offer this option to our patients.”
This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase 2 trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of Reolysin(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II and Phase II human trials using Reolysin(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.

About CTRC
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is among the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.